Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Knigge

Showing results (31-40 of 108) with videos related to

Pageof 11
Sort By:
Plos One|March 15, 2014
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in miceCamilla Bardram Johnbeck, Mette Munk Jensen, Carsten Haagen Nielsen, et al.
Journal of Cancer|August 27, 2014
Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasIngrid Holst Olsen, Ulrich Knigge, Birgitte Federspiel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Neuroendocrinology|October 28, 2015
Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-Three Cases Evaluated according to the WHO 2010 ClassificationIben Engelund Luna, Nina Monrad, Tina Binderup, et al.
Diagnostics (Basel, Switzerland)|May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the PancreasElisabetta Perrone, Kriti Ghai, Aleksandr Eismant, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Thescientificworldjournal|September 14, 2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomasIngrid H Olsen, Jens B Sørensen, Birgitte Federspiel, et al.
Pediatric Blood & Cancer|November 23, 2024
Pediatric Neuroendocrine Tumors in Denmark: Incidence, Management, and Outcome From 1995 to 2020Mona P Ankerstjerne, Sara Giovannoni, Lene G Christensen, et al.
BMC Cancer|January 12, 2020
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasmsKirstine Nielsen, Tina Binderup, Seppo W Langer, et al.
Current Oncology Reports|January 3, 2024
Appendiceal Neuroendocrine Neoplasms: an Update for 2023Pernille Holmager, Seppo W Langer, Andreas Kjaer, et al.
Pageof 11

Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Plos One|March 15, 2014
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in miceCamilla Bardram Johnbeck, Mette Munk Jensen, Carsten Haagen Nielsen, et al.
Journal of Cancer|August 27, 2014
Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasIngrid Holst Olsen, Ulrich Knigge, Birgitte Federspiel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Neuroendocrinology|October 28, 2015
Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-Three Cases Evaluated according to the WHO 2010 ClassificationIben Engelund Luna, Nina Monrad, Tina Binderup, et al.
Diagnostics (Basel, Switzerland)|May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the PancreasElisabetta Perrone, Kriti Ghai, Aleksandr Eismant, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Thescientificworldjournal|September 14, 2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomasIngrid H Olsen, Jens B Sørensen, Birgitte Federspiel, et al.
Pediatric Blood & Cancer|November 23, 2024
Pediatric Neuroendocrine Tumors in Denmark: Incidence, Management, and Outcome From 1995 to 2020Mona P Ankerstjerne, Sara Giovannoni, Lene G Christensen, et al.
BMC Cancer|January 12, 2020
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasmsKirstine Nielsen, Tina Binderup, Seppo W Langer, et al.
Current Oncology Reports|January 3, 2024
Appendiceal Neuroendocrine Neoplasms: an Update for 2023Pernille Holmager, Seppo W Langer, Andreas Kjaer, et al.
Pageof 11